Seqens Seqens

X
[{"orgOrder":0,"company":"3M Company","sponsor":"IDRI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Adjuvanted Vaccine Candidate Using IDRI Formulation Demonstrates Coronavirus Pan-Vaccine Potential","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals for aluminum hydrogen sulfate

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Vaccine candidate, which combines a nanoparticle developed by a Duke-led research team with IDRI’s novel formulation of 3M’s “3M-052” compound Produced more “broadly neutralizing antibodies” against several strains of coronavirus, including bat coronaviruses.

            Lead Product(s): 3M-052,Potassium Alum

            Therapeutic Area: Infections and Infectious Diseases Product Name: 3M-052

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: IDRI

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 03, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY